We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > two-drug

News List

ViiV and Janssen seek European approval for HIV two-drug regimen pharmaceutical-technology
July 31, 2019
ViiV Healthcare and Janssen Pharmaceutical have filed separate marketing authorisation applications (MAA) for the use of their respective drugs, cabotegravir and rilpivirine, as a combination therapy in adults with HIV infection.
ViiV Healthcare's Dovato approved in US as first two-drug single-tablet regimen for patients with treatment-naïve HIV firstwordpharma
April 09, 2019
The FDA on Monday announced the approval of ViiV Healthcare's Dovato (dolutegravir/lamivudine) for ^
ViiV's two-drug regimen gets EU approval for HIV-1 pharmafile
May 25, 2018
ViiV Healthcare has announced that its HIV therapy Juluca (dolutegravir/rilpivirine) has been awarded marketing authorisation in the EU from the European Commission, making it the first available two-drug regimen, daily single pill solution for the type 1